{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:16:51Z","timestamp":1790983011051,"version":"4.1.0"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and multifocal motor neuropathy (MMN) are immune-mediated peripheral neuropathies that may follow a progressive course and be refractory and poorly tolerated to standard immunomodulatory treatments. Therapeutic options for such patients remain limited. We report two patients with immune-mediated neuropathies\u2014one with typical CIDP and one with MMN\u2014who were treated with low-dose intermittent subcutaneous cladribine. Clinical outcomes were assessed using the Medical Research Council (MRC) sum score and the Inflammatory Neuropathy Cause and Treatment (INCAT) disability score. Both patients demonstrated clinically meaningful and sustained improvements in muscle strength and functional disability lasting up to 24 months after treatment completion. Cladribine was well tolerated; transient lymphopenia occurred in one patient without serious adverse events. These cases suggest that cladribine may represent a potential therapeutic option for selected patients with CIDP or MMN. Further studies are warranted to confirm efficacy and safety.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1782666","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:48:15Z","timestamp":1785905295000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Cladribine treatment in chronic inflammatory demyelinating polyradiculoneuropathy and multifocal motor neuropathy: two case reports"],"prefix":"10.3389","volume":"17","author":[{"given":"Konrad","family":"Rejdak","sequence":"first","affiliation":[{"name":"Department of Neurology, Medical University of Lublin","place":["Lublin, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Bielewicz","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of Lublin","place":["Lublin, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Kami\u0144ski","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of Lublin","place":["Lublin, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Grieb","sequence":"additional","affiliation":[{"name":"Department of Experimental Pharmacology, Mossakowski Medical Research Institute, Polish Academy of Sciences","place":["Warsaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24087288","article-title":"Immune-mediated neuropathies: pathophysiology and management","volume":"24","author":"Shastri","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14959","article-title":"European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy\u2014second revision","volume":"28","author":"Van den Bergh","year":"2021","journal-title":"Eur J Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.13184","article-title":"Pathology explains various mechanisms of autoimmune inflammatory peripheral neuropathies","volume":"34","author":"Vallat","year":"2024","journal-title":"Brain Pathol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-020-00190-8","article-title":"Pathophysiology of chronic inflammatory demyelinating polyneuropathy: insights into classification and therapeutic strategy","volume":"9","author":"Koike","year":"2020","journal-title":"Neurol Ther"},{"key":"B5","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1529-8027.2010.00290.x","article-title":"European Federation of Neurological Societies\/Peripheral Nerve Society guideline on management of multifocal motor neuropathy\u2014first revision","volume":"15","year":"2010","journal-title":"J Peripher Nerv Syst"},{"key":"B6","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/0165-5728(95)98907-s","article-title":"Cladribine treatment of multiple sclerosis","volume":"344","author":"Grieb","year":"1994","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14109","article-title":"Cladribine in myasthenia gravis: a pilot open-label study","volume":"27","author":"Rejdak","year":"2020","journal-title":"Eur J Neurol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14904","article-title":"Cladribine suppresses disease activity in neuromyelitis optica spectrum disorder: a 2-year follow-up study","volume":"28","author":"Rejdak","year":"2021","journal-title":"Eur J Neurol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1177\/17562864221137129","article-title":"Repurposing MS immunotherapies for CIDP and other autoimmune neuropathies: unfulfilled promise or efficient strategy","volume":"16","author":"K\u00f6hle","year":"2023","journal-title":"Ther Adv Neurol Disord"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/17582024.2025.2520709","article-title":"A drug evaluation narrative review of cladribine as a treatment for multiple sclerosis","volume":"15","author":"Martin","year":"2025","journal-title":"Neurodegener Dis Manag"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2011.09.004","article-title":"Cladribine inhibits cytokine secretion by T cells independently of deoxycytidine kinase activity","author":"Laugel","year":"2011","journal-title":"J Neuroimmunol"},{"key":"B13","article-title":"Cladribine injection: drug information","volume-title":"U.s. National Library of Medicine","year":"2024"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3109\/10428190009113398","article-title":"Guillain\u2013Barr\u00e9 syndrome following treatment with cladribine for hairy cell leukemia","volume":"39","author":"Sarmiento","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000031785.78242.B6","article-title":"Cladribine in the treatment of IgM paraproteinemic polyneuropathy","volume":"59","author":"Ghosh","year":"2002","journal-title":"Neurology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1017\/cjn.2021.56","article-title":"Autologous hematopoietic stem cell transplantation for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"48","author":"Masson-Roy","year":"2021","journal-title":"Can J Neurol Sci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci14080764","article-title":"Unravelling the acute, chronic and steroid-refractory management of high-grade neurological immune-related adverse events: a call to action","volume":"14","author":"Malvaso","year":"2024","journal-title":"Brain Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.10.006","article-title":"Cladribine induces long-lasting oligoclonal band disappearance in relapsing multiple sclerosis patients: a 10-year observational study","volume":"27","author":"Rejdak","year":"2019","journal-title":"Mult Scler Relat Disord"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1782666\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:48:26Z","timestamp":1785905306000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1782666\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":18,"alternative-id":["10.3389\/fimmu.2026.1782666"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1782666","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"article-number":"1782666"}}